TITLE

Editor's Commentary

PUB. DATE
June 2009
SOURCE
Respiratory Care;Jun2009, Vol. 54 Issue 6, p697
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
An introduction to the journal is presented in which the editor discusses an article on cystic fibrosis (CF) lung disease, the various airway-clearance therapies that can be used for patients with CF and aerosol delivery devices for CF.
ACCESSION #
41427587

 

Related Articles

  • Inhaled hypertonic saline in cystic fibrosis.  // Archives of Disease in Childhood;Jun2006, Vol. 91 Issue 6, p468 

    The article looks at two studies on the effectiveness of regular inhalation of hypertonic saline in young patients with cystic fibrosis. In Australia, 164 patients inhaled saline twice a day for 48 weeks. In the United States, 24 patients inhaled nebulized hypertonic saline four times daily for...

  • Nebulized Antibiotics in Cystic Fibrosis. Sermetgaudelus, I.; Lecocguic, Y.; Ferroni, A.; Clairicia, M.; Barthe, J.; Delaunay, J.; Brousse, V.; Lenoir, G. // Pediatric Drugs;2002, Vol. 4 Issue 7, p455 

    Nebulization is a useful administration route in cystic fibrosis (CF) as it delivers antibiotics directly to the endobronchial site of infection and is associated with decreased toxicity because of limited systemic absorption. It is assumed that the concentration of antibiotics in bronchial...

  • Prolastin aerosol therapy and sputum taurine in cystic fibrois. Cantin, André M.; Berthiaume, Yves; Cloutier, Diane; Martel, Marc // Clinical & Investigative Medicine;Aug2006, Vol. 29 Issue 4, p201 

    The article discusses the effects of Prolastin aerosol therapy on airway inflammation in cystic fibrosis. Prolastin is a therapeutic preparation of alpha-1 proteinase inhibitor, a neutrophil elastase inhibitor. It also presents a conclusion that aerosol therapy with Prolastin in patients with...

  • Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review. Kirkby, Stephen; Novak, Kimberly; McCoy, Karen // Core Evidence;2011, Vol. 6 Issue 1, p59 

    Cystic fibrosis (CF) is a genetic disease caused by abnormal chloride transport across cellular membranes. In the respiratory tract, this molecular defect causes obstruction of the airways by mucus and chronic endobronchial infection. The majority of patients suffer early death from chronic...

  • Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Downs, J. A.; Roberts, C. M.; Blackmore, A. M.; Le Sou�f, P. N.; Jenkins, S. C. // Chronic Respiratory Disease;2006, Vol. 3 Issue 1, p19 

    Adherence to recommended aerosol medicines and airway clearance techniques (ACT) for children with cystic fibrosis (CF) requires self-management skills. A multi-centre, randomized, controlled trial was conducted to investigate the effectiveness of a self-management education programme called...

  • The Use of Phages for the Removal of Infectious Biofilms. Azeredo, J.; Sutherland, I. W. // Current Pharmaceutical Biotechnology;Aug2008, Vol. 9 Issue 4, p261 

    Biofilm formation occurs spontaneously on both inert and living systems and is an important bacterial survival strategy. In humans bioflms are responsible for many pathologies, most of them associated with the use of medical devices. A major problem of biofilms is their inherent tolerance to...

  • New Developments in Inhaled Antibiotics for the Treatment of Pseudomonas aeruginosa. Hofmann, Thomas // Current Pharmaceutical Design;2/11/2012, Vol. 18 Issue 5, p683 

    The field of inhaled antibiotics that target Pseudomonas aeruginosa infections has made substantial contributions to the health, disease management, and life expectancies of individuals with cystic fibrosis (CF) over the last three decades [1-3]. This paper reviews some of the recent clinical...

  • Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung. McLachlan, G; Davidson, H; Holder, E; Davies, L A; Pringle, I A; Sumner-Jones, S G; Baker, A; Tennant, P; Gordon, C; Vrettou, C; Blundell, R; Hyndman, L; Stevenson, B; Wilson, A; Doherty, A; Shaw, D J; Coles, R L; Painter, H; Cheng, S H; Scheule, R K // Gene Therapy;Oct2011, Vol. 18 Issue 10, p996 

    We use both large and small animal models in our pre-clinical evaluation of gene transfer agents (GTAs) for cystic fibrosis (CF) gene therapy. Here, we report the use of a large animal model to assess three non-viral GTAs: 25 kDa-branched polyethyleneimine (PEI), the cationic liposome (GL67A)...

  • Clinical Pharmacology Study of Bramitob, a Tobramycin Solution for Nebulization, in Comparison with Tobi. Poli, Gianluigi; Acerbi, Daniela; Pennini, Roberto; Raschini, Annamaria Soliani; Corrado, Mario Ermanno; Eichler, Hans Georg; Eichler, Irmgard // Pediatric Drugs;2007 Supplement, Vol. 9, p3 

    Background and objectives: To compare in vitro characteristics and pharmacokinetics of Bramitob®, a preservative-free tobramycin solution for nebulization, and Tobi® in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa infection. Methods: In vitro characteristics of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics